Author Archive

CGRP Update!! All your questions answered.

1st August 2018

CGRP Update Following member’s queries and questions around the introduction of this new drug and in response to the large volume of online comments and questions, (read our original press release here) The Migraine Association sought clarification on a number of issues with Novartis who have confirmed the following: Erenumab is the first and only treatment specifically designed for migraine prevention to be approved in the... [read more]


Patient Information Evening, Louth, 26th April

9th April 2018

This seminar is presented by Dr Raeburn Forbes - a practising neurologist from Northern Ireland and one of Ireland's leading migraine and headache experts. Dr. Forbes is author of The Billionaire's Book of Headaches and the accompanying free online headache self management course, an innovative online course to help you better understand and manage your migraines. "What you will read here is what I tell my own patients. Many people with... [read more]


Notice of AGM 2018

7th March 2018

Please note the Annual General Meeting of The Migraine Association of Ireland will take place on Monday, 23rd April at 5... [read more]


Call for posters for NAI Conference

9th January 2018

Poster presentations are invited on basic, clinical and social research into brain conditions to feature at the Neurological Alliance of Ireland & Irish Brain Council Joint Conference “Research & Healthcare Responses to the Challenge of Brain Conditions in Ireland” Science Gallery Dublin 6th March 2018. Applicants should aim to submit abstracts no later than Friday 9th February 2018 to brainresearch2018@gmail.com including contact... [read more]


New Drugs for Migraine on the Way

6th December 2017

Calcitonin gene-related receptor (CGRP) antagonists are the most important medications in advanced stage clinical development for the treatment of both the acute migraine attack and the prevention of frequent attacks. Clinical trials on two of the antibodies have now been published in the New England Journal of Medicine. One antibody, Erenumab made by Novartis, was trialed on 955 patients with episodic migraine. At the start of the... [read more]


Author Archive

CGRP Update!! All your questions answered.

1st August 2018

CGRP Update Following member’s queries and questions around the introduction of this new drug and in response to the large volume of online comments and questions, (read our original press release here) The Migraine Association sought clarification on a number of issues with Novartis who have confirmed the following: Erenumab is the first and only treatment specifically designed for migraine prevention to be approved in the... [read more]


Patient Information Evening, Louth, 26th April

9th April 2018

This seminar is presented by Dr Raeburn Forbes - a practising neurologist from Northern Ireland and one of Ireland's leading migraine and headache experts. Dr. Forbes is author of The Billionaire's Book of Headaches and the accompanying free online headache self management course, an innovative online course to help you better understand and manage your migraines. "What you will read here is what I tell my own patients. Many people with... [read more]


Notice of AGM 2018

7th March 2018

Please note the Annual General Meeting of The Migraine Association of Ireland will take place on Monday, 23rd April at 5... [read more]


Call for posters for NAI Conference

9th January 2018

Poster presentations are invited on basic, clinical and social research into brain conditions to feature at the Neurological Alliance of Ireland & Irish Brain Council Joint Conference “Research & Healthcare Responses to the Challenge of Brain Conditions in Ireland” Science Gallery Dublin 6th March 2018. Applicants should aim to submit abstracts no later than Friday 9th February 2018 to brainresearch2018@gmail.com including contact... [read more]


New Drugs for Migraine on the Way

6th December 2017

Calcitonin gene-related receptor (CGRP) antagonists are the most important medications in advanced stage clinical development for the treatment of both the acute migraine attack and the prevention of frequent attacks. Clinical trials on two of the antibodies have now been published in the New England Journal of Medicine. One antibody, Erenumab made by Novartis, was trialed on 955 patients with episodic migraine. At the start of the... [read more]